ArticleAdvances in therapy2025
Elevating the Patient Voice: Understanding Treatment Preferences in Patients with Advanced Prostate Cancer.
Article in Advances in therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWith multiple oral medications currently available for patients with prostate cancer, there is a need to understand how patients' preferences and experiences are impacted by several factors including pill burden and dosing frequency. This study aimed to understand medication preferences from patients with advanced prostate cancer (APC).
methodsWe conducted a cross-sectional, online survey of patients with APC living in the USA.
resultsThe survey was completed by 100 patients with a median age of 65 years (range 35-79). Most patients were White (53%) with 31% Black and 15% Hispanic. Nearly half (48%) reported taking more than five pills per day and 50% reported taking more than three prescription medications per day. Nearly two-thirds (63%) reported difficulty remembering to take pills multiple times per day and 91% said they would choose a one-pill-once-daily option over a multi-pill regimen. Twenty-two (22%) patients had difficulty swallowing pills or were unsure. Of these 22, 21 (95%) considered it important that a pill can be dispersed in water or applesauce. Most patients (81%) had undergone chemotherapy previously and 80% reported taking oral medications for prostate cancer. Eighty-nine (89%) patients said they would prefer an oral treatment option compared to intravenous chemotherapy.
conclusionMost patients prefer a one-pill-once-daily regimen. Most patients prefer the option of an oral treatment regimen over intravenous chemotherapy. When discussing treatment options, providers should consider the individual patient's preferences and engage in shared decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.